Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUBILUS study of two-dose nirsevimab in high-risk Japanese infants
jRCT2031230256Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nirsevimab in respiratory syncytial virus disease (RSV), sponsored by AstraZeneca. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent serious adverse events and 2 more. Started Jul 2023; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031230256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230256.